Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development - GBI Research Reports

Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development

Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development - GBI Research Reports
Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development
Published Jul 06, 2011
132 pages — Published Jul 06, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, a leading business intelligence provider, has released its latest research Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development, which provides insights into the unmet needs targeted by late stage pipeline molecules across major therapy areas. The report examines the safety, efficacy parameters of molecules in development. The report includes insights into the R&D pipeline various therapy areas and identifies potential blockbusters.

In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by GBI Researchs team of experts.

Scope

The scope of this report includes -
- Profiles of promising late stage pipeline molecules across various therapy areas
- Analysis of safety, efficacy, mechanism of actions of major pipeline drugs targeted at major therapy areas
- Comparison of late stage drugs based on safety, efficacy, mechanism of action, unmet need targeted and stage of disease targeted

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Build effective strategies to launch their pipeline products by identifying geographies with high potential for growth.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

  
Source:
Document ID
GBIHC112MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development" Jul 06, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Comparative-Analysis-of-Late-Stage-Pipeline-Molecules-in-Major-Indications-Oncology-Pipeline-Leads-with-Most-Promising-Molecules-in-Late-Stage-Development-2115-237>
  
APA:
GBI Research Reports. (2011). Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development Jul 06, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Comparative-Analysis-of-Late-Stage-Pipeline-Molecules-in-Major-Indications-Oncology-Pipeline-Leads-with-Most-Promising-Molecules-in-Late-Stage-Development-2115-237>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.